Curanex Pharmaceuticals (NASDAQ:CURX) Announces Earnings Results

Curanex Pharmaceuticals (NASDAQ:CURX) announced its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share for the quarter, FiscalAI reports.

Curanex Pharmaceuticals Stock Down 4.0%

Shares of CURX traded down $0.01 during mid-day trading on Friday, reaching $0.30. 82,656 shares of the stock traded hands, compared to its average volume of 119,080. The firm has a market cap of $8.52 million and a price-to-earnings ratio of -1.11. The stock has a fifty day simple moving average of $0.43 and a 200 day simple moving average of $0.42. Curanex Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $9.18.

Institutional Trading of Curanex Pharmaceuticals

An institutional investor recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC acquired a new stake in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 64,067 shares of the company’s stock, valued at approximately $46,000.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.